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Asymmetric dimethylarginine: A cardiovascular risk factor in from nuclear proteins involved in RNA processing and
renal disease? Endothelial dysfunction due to reduced avail- transcriptional control. The enzyme protein arginine meth-
ability of nitric oxide (NO) is an early step in the course of yltransferase type I (PRMT I) forms ADMA, whereasatherosclerotic vascular disease. NO is synthesized from the
PRMT II forms symmetric dimethylarginine (SDMA)amino acid L-arginine by the action of the NO synthase (NOS),
(i.e., the stereoisomer of ADMA with no known effectwhich can be blocked by endogenous inhibitors such as asym-
metric dimethylarginine (ADMA). In laboratory animals, ad- on NOS). A number of cell types, including human endo-
ministration of ADMA significantly reduces NO generation, thelial cells, elaborate ADMA. The substance is excreted
and causes an increase of blood pressure and renal vascular
by renal route to some extent, but the major metabolicresistance. In clinical studies, a strong correlation between in-
pathway is degradation by the enzyme dimethylargininecreased ADMA blood levels and impaired endothelial-depen-
dent vasodilatation, and cardiovascular morbidity and mortal- dimethylaminohydrolase (DDAH), which hydrolyzes
ity has been documented in different populations, including in ADMA to dimethylamine and L-citrulline (Fig. 1). Thus
patients with renal disease. Thus, ADMA seems to be the culprit, far, two isoforms of DDAH have been characterized;
and not just an innocent biochemical bystander, of the athero-
DDAH II is the predominant form in tissues expressingsclerotic disease process. Moreover, reduced NO availability
endothelial NOS. Colocalization of DDAH and NOSis involved in the progression of renal disease, and increased
ADMA blood levels may contribute to this process. Interven- supports the hypothesis that intracellular ADMA con-
tions that lower ADMA blood levels in renal patients could, centration is actively and cell-specifically regulated in
therefore, modulate their atherogenic profile and interfere with NO-generating cells [2]. Since NO has tremendous bio-progression of renal failure.
logical activity, its blood and/or tissue concentration
must be kept within narrow limits in order to prevent
harmful effects on cell activity. This could be accom-Nitric oxide (NO) is a very active, but short living,
plished by cell-specific endogenous NOS inhibitors, suchmolecule that is released in the circulation from endothe-
as ADMA, and thus explain the L-arginine paradox.lial cells. It is a potent vasodilator that regulates vascular
The NO amino acid precursor L-arginine is found in theresistance and tissue blood flow. In addition, NO inhibits
mammalian organism at concentrations by far exceedingkey processes of atherosclerosis, such as monocyte endo-
the KM value for the rate limiting enzyme NOS, so that,thelial adhesion, platelet aggregation, and vascular smooth
theoretically, administration of L-arginine should notmuscle cell proliferation. Hence, endothelial dysfunction
enhance NO formation. Several in vivo studies have doc-due to reduced NO availability is an early step in the
umented, however, that administration of L-arginine en-course of atherosclerotic vascular disease [1]. NO is syn-
hances NO production, possibly because the additionalthesized by stereospecific oxidation of the terminal gua-
L-arginine antagonizes the action of endogenous NOSnidino nitrogen of the amino acid, L-arginine, by the
inhibitors [3].action of a family of NOS. The synthesis of NO can be
blocked, however, by inhibition of the NOS active site
with guanidino-substituted analogs of L-arginine, such IS NOS INHIBITION BY ADMA
as ADMA [1]. BIOLOGICALLY RELEVANT?
ADMA is released after posttranslational methylation
Data from experimental studies document that patho-
physiologically relevant ADMA blood levels (between
2–10 mol/L) significantly inhibit NOS in cultured endo-Key words: asymmetric dimethylarginine, nitric oxide, atherosclerosis,
renal disease. thelial cells and in isolated human blood vessels, thereby
reducing NO generation [1]. Administration of ADMA to 2003 by the International Society of Nephrology
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ADMA levels in these subjects were significantly corre-
lated with the intima-media thickness of the carotid ar-
teries as measured by high-resolution sonography. Thus,
chronically elevated plasma levels may be of relevance
in human vascular pathology (i.e., ADMA being the
culprit and not just an innocent biochemical bystander
of the atherosclerotic disease process). The cause for the
increase of ADMA blood levels in nonrenal populations
is not completely understood; however, inhibition of
DDAH activity by hypercholesterolemia (especially
LDL-cholesterol), hyperglycemia, and hyperhomocysti-
nemia may play an important role [1, 10, 11] (Fig. 1).
ADMA, ATHEROSCLEROSIS, AND PROGRESSION
Fig. 1. Biochemical pathway for generation and degradation of IN PATIENTS WITH RENAL DISEASEADMA.
Impaired NO-mediated endothelial-dependent vaso-
dilatation (i.e., the hallmark of early atherosclerosis) has
been reported in children and adults with chronic renal
laboratory animals caused an increase of blood pressure failure, and even in patients with adult polycystic kidney
and renal, mesenteric, and hindquarter vascular resis- disease and normal renal function [12]. Furthermore,
tance [4]. In addition, a recent experiment with trans- L-arginine, but not D-arginine, restores endothelial func-
genic animals harboring the human DDAH gene re- tion in patients with end-stage renal disease (ESRD)
vealed that increased DDAH activity lowers ADMA independently of hemodialysis treatment [13]. This latter
blood concentrations and, in parallel, significantly re- observation points to reduced availability of NO in pa-
duces blood pressure (abstract; Dayoub H et al, Eur tients with ESRD.
Heart J :132A, 2002]. In humans, indirect evidence for In 1992, Vallance et al reported increased plasma con-
a biologically relevant action of ADMA comes from a centrations of methylarginines (i.e., ADMA and SDMA)
recent study in renal patients, in whom plasma ADMA in a small group of patients with ESRD [14]. They hy-
levels were increased four times as compared with pothesized that the high incidence of hypertension and
healthy controls—their blood markedly inhibited NO atherosclerosis in patients with terminal renal failure
production in cultured endothelial cells ex vivo [5]. Fur- might be caused, at least in part, by dysfunction of the
thermore, Chan et al have found that mononuclear cell L-arginine/NO pathway secondary to accumulation of
adhesiveness significantly correlates with elevated plasma ADMA due to declining renal excretion. Indeed, the
ADMA concentrations in hypercholesterolemic subjects same authors demonstrated that infusion of ADMA into
[6]. In cell culture, the adhesiveness of these cells was the brachial artery attenuated endothelial-dependent va-
enhanced by coculturing them with ADMA-stimulated sodilatation in healthy volunteers [14]. Several recent
studies have confirmed markedly increased plasma ADMAvascular endothelial cells. We were able to demonstrate
levels in patients with renal failure [15, 16] (Table 1).that systemic administration of ADMA in healthy sub-
However, the assumption that decreased urinary excre-jects causes a sustained reduction of NO production and
tion is the main cause of elevated plasma ADMA con-renal perfusion, and increase in blood pressure (abstract;
centrations in ESRD patients has been questioned byKielstein JT et al, Kidney Blood Press Res 25:130A, 2002).
the observation that SDMA, which is not degraded byThus, ADMA is a biologically active NOS inhibitor.
DDAH, accumulates eight times more than ADMA in
patients with ESRD. Furthermore, markedly increased
ADMA: A NEW EMERGING CARDIOVASCULAR plasma ADMA concentrations are found even in patients
RISK FACTOR? with incipient renal disease (i.e., patients with normal
A growing number of published clinical studies in non- renal function as documented by measurement of true
renal patients documented a strong correlation between glomerular filtration rate using inulin clearance) [17].
increased ADMA blood levels and cardiovascular mor- Interestingly, ADMA levels were elevated independent
bidity and mortality in different populations [1, 7–9]. of the type of renal disease. This observation favors the
Results from a cross-sectional study in 116 otherwise hypothesis that impaired ADMA degradation by (renal)
healthy subjects revealed that ADMA blood levels were DDAH, rather than reduced renal excretion, is the main
positively correlated with age, mean arterial blood pres- cause of increased plasma ADMA concentrations in pa-
tients with renal disease. DDAH is present in abundancesure, and glucose intolerance [8]. Most strikingly, plasma
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Table 2. Clearance of creatinine, urea, ADMA, and SDMATable 1. ADMA blood levels in renal patients
and other populations in patients on maintance hemodialysis
Creatinine Urea ADMA SDMAADMA blood level
Reference Population lmol/L
Clearance mL/min 1635 1756 798 1356
17 Incipient renal disease 4.20.9 Abbreviations are: ADMA, asymmetric dimethylarginine and SDMA, sym-
Controls 1.40.7 metric dimethylarginine.
14 Chronic renal failure 8.70.7a
Controls 1.20.1a
15 End-stage renal disease 6.00.5
Controls 1.00.1
6 Hypercholesterolemia 2.10.2 administration of L-arginine in order to overcome NOS
Controls 1.30.2 inhibition [1]. To date, a large body of evidence has been
7 Peripheral occlusive disease IV 3.50.3
accumulated regarding the beneficial role of L-arginineControls 1.30.1
Elderly subjects 3.50.1 administration on several aspects of endothelial dysfunc-
Young controls 1.30.1 tion, but surprisingly few studies have specifically ad-
a Dimethylarginines dressed the potential role of ADMA. Bo¨ger et al showed
that administration of L-arginine to patients with periph-
eral vascular disease not only increased L-arginine/ADMA
ratio, and thereby NO production, but also amelioratedin endothelial cells within the glomerulus and renal ves-
clinical symptoms in patients [20]. Moreover, recent stud-sels, and particularly in renal tubular cells [2]. It regulates
ies in patients with essential hypertension and type 2intracellular methylarginine levels, thereby governing
diabetes mellitus have revealed that pharmacologiccell-specific L-arginine uptake and NO generation in tu-
treatment with ACE inhibitors, AT1-receptor blockers,bular cells. Destruction of DDAH-rich renal tissue could,
and insulin-sensitizing agents may reduce ADMA bloodtherefore, theoretically impair renal degradation of
levels, possibly via enhancement of DDAH activity [10].ADMA. Whatever the cause of increased plasma ADMA
The results of studies examining the effect of dialysisconcentrations in patients with renal disease may be, re-
treatment on ADMA blood levels in patients with ESRDsults of recent in vitro studies suggest that ADMA concen-
are controversial. Some authors have found a significanttrations in patients with ESRD are high enough to suffi-
reduction of ADMA blood levels after dialysis treat-ciently decrease NO production [5]. Indirect evidence for
ment, while others have not. We have recently exploreda pathophysiologic role of ADMA in this population in-
this issue using a single-pass batch dialysis system thatclude observations that, in ESRD patients with manifest
offers a complete collection of the spent dialysate. De-atherosclerosis, plasma ADMA levels were significantly
spite its relatively low molecular weight, comparablehigher than in renal patients without signs of atheroscle-
with that of urea, the dialysance of ADMA was consider-rotic disease [15]. Last, but not least, in a prospective
ably lower than that of urea (Table 2). Further studiesstudy in 225 patients with ESRD, plasma ADMA con-
are warranted in order to evaluate potential mechanismscentrations were not only significantly related to the se-
of ADMA elimination in patients with ESRD.verity of carotid atherosclerosis but, in addition, were the
second strongest predictor (after age) of cardiovascular Reprint requests to Danilo Fliser, M.D., Department of Internal Medi-
mortality among several (traditional) risk factors as- cine, Division of Nephrology, Hannover Medical School, Carl-Neuberg-
Strasse 1, 30625 Hannover, Germany.sessed [16].
E-mail: fliser.danilo@mh-hannover.deAnother important aspect of NO inhibition in renal
patients is progression of renal disease. Past and more
REFERENCESrecent experimental studies have revealed that reduced
1. Cooke JP: Does ADMA cause endothelial dysfunction? Arte-bioavailability of NO plays a critical role in the progres-
rioscler Thromb Vasc Biol 20:2032.-2037, 2000sion of renal disease, and increased ADMA blood levels
2. Tojo A, Welch WJ, Bremer V, et al: Colocalization of demethylat-
may contribute to this process [18]. In this respect, it is ing enzymes and NOS and functional effects of methylarginines
in rat kidney. Kidney Int 52:1593–1601, 1997of interest that increased plasma ADMA levels predict
3. Bode-Bo¨ger SM, Boger RH, Kienke S, et al: Elevated L-arginine/the increase of blood pressure in elderly subjects, and,
dimethylarginine ratio contributes to enhanced systemic NO pro-
even more importantly, they are significantly associated duction by dietary L-arginine in hypercholesterolemic rabbits. Bio-
chem Biophys Res Commun 219:598–603, 1996with the age-related decrease in renal perfusion [19].
4. Gardiner SM, Kemp PA, Bennett T, et al: Regional and cardiacFurther studies are, therefore, warranted to clarify the
haemodynamic effects of NG, NG,dimethyl-L-arginine and their
role of ADMA in the progression of renal disease. reversibility by vasodilators in conscious rats. Br J Pharmacol
110:1457–1464, 1993
5. Xiao S, Wagner L, Schmidt RJ, et al: Circulating endothelial nitric
oxide synthase inhibitory factor in some patients with chronic renalPERSPECTIVE
disease. Kidney Int 59:1466–1472, 2001
Since ADMA is thought to be a competitive NOS 6. Chan JR, Boger RH, Bode-Bo¨ger SM, et al: Asymmetric dimethy-
larginine increases mononuclear cell adhesiveness in hypercholes-inhibitor, the logical therapeutic intervention would be
Fliser et al: ADMA in renal patientsS-40
terolemic humans. Arterioscler Thromb Vasc Biol 20:1040–1046, 14. Vallance P, Leone A, Calver A, et al: Accumulation of an endog-
2000 enous inhibitor of nitric oxide synthesis in chronic renal failure.
7. Boger RH, Bode-Bo¨ger SM, Thiele W, et al: Biochemical evi- Lancet 339:572–575, 1992
dence for impaired nitric oxide synthesis in patients with peripheral 15. Kielstein JT, Boger RH, Bode-Bo¨ger SM, et al: Asymmetric
arterial occlusive disease. Circulation 95:2068–2074, 1997 dimethylarginine plasma concentrations differ in patients with end-
8. Miyazaki H, Matsuoka H, Cooke JP, et al: Endogenous nitric stage renal disease: Relationship to treatment method and athero-
oxide synthase inhibitor: a novel marker of atherosclerosis. Circula- sclerotic disease. J Am Soc Nephrol 10:594–600, 1999
tion 99:1141–1146, 1999 16. Zoccali C, Bode-Bo¨ger S, Mallamaci F, et al: Plasma concentra-
9. Valkonen VP, Paiva H, Salonen JT, et al: Risk of acute coronary tion of asymmetrical dimethylarginine and mortality in patients
events and serum concentration of asymmetrical dimethylarginine. with end-stage renal disease: A prospective study. Lancet 358:2113–
Lancet 358:2127–2128, 2001 2117, 2001
10. Lin KY, Ito A, Asagami T, et al: Impaired nitric oxide synthase 17. Kielstein JT, Boger RH, Bode-Bo¨ger SM, et al: Marked increase
pathway in diabetes mellitus: Role of asymmetric dimethylarginine of asymmetric dimethylarginine in patients with incipient primaryand dimethylarginine dimethylaminohydrolase. Circulation 106:987–
chronic renal disease. J Am Soc Nephrol 13:170–176, 2002992, 2002
18. Wagner L, Riggleman A, Erdely A, et al: Reduced nitric oxide11. Stuhlinger MC, Tsao PS, Her JH, et al: Homocysteine impairs
synthase activity in rats with chronic renal disease due to glomeru-the nitric oxide synthase pathway: Role of asymmetric dimethylar-
lonephritis. Kidney Int 62:532–536, 2002ginine. Circulation 104:2569–2575, 2001
19. Kielstein JT, Bode-Boger SM, Fruelich JC, Ritz E, Haller H,12. Wang D, Iversen J, Strandgaard S: Endothelium-dependent re-
Fliser D: Asymmetric dimethyl arginine (ADMA), blood pressurelaxation of small resistance vessels is impaired in patients with
and renal perfusion in elderly subjects. Circulation, 2003 (in press)autosomal dominant polycystic kidney disease. J Am Soc Nephrol
20. Boger RH, Bode-Bo¨ger SM, Thiele W, et al: Restoring vascular11:1371–1376, 2000
nitric oxide formation by L-arginine improves the symptoms of13. Hand MF, Haynes WG, Webb DJ: Hemodialysis and L-arginine,
intermittent claudication in patients with peripheral arterial occlu-but not D-arginine, correct renal failure-associated endothelial
dysfunction. Kidney Int 53:1068–1077, 1998 sive disease. J Am Coll Cardiol 32:1336–1344, 1998
